A Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparation method

Abstract

The invention discloses a Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof, and relates to the technical field of cardiovascular and cerebrovascular drugs. The Chinese medicine composition comprises the following components: ginkgo leaf, sophora japonica flower, kudzu root, ginkgo, codonopsis pilosula, chrysanthemum, nelumboide, jujube, angelica, gastrodia elata, purslane, wolfberry, selfheal, cornus officinalis, sappan wood, eucommia leaf, lithospermum officinale and liquorice. The invention combines the above raw materials, extracts the effective components of the raw materials, and makes the components of the Chinese medicine components play a synergistic effect, respectively performs comprehensive conditioning from multiple aspects such as lung, liver, heart, kidney and spleen, effectively improves the immune repair ability of patients, has the effects of lowering blood lipid and blood sugar, lowering blood pressure and protecting heart and brain, and has a significant therapeutic effect on cardiovascular and cerebrovascular diseases.

Description

Technical Field

[0001] The present invention relates to the technical field of cardiovascular and cerebrovascular drugs, and more specifically to a Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof. Background Art

[0002] Cardiovascular and cerebrovascular diseases refer to diseases caused by ischemia or bleeding of the heart due to hardening of the heart and arteries, including coronary heart disease, angina pectoris, hypertension, arrhythmia, myocardial infarction, cerebral infarction, etc. Cardiovascular and cerebrovascular diseases have always been known as the number one killer threatening human health. Hypertension, hyperlipidemia, coronary heart disease, and diabetes have become the "plague of the times." However, with the improvement of social living standards and the acceleration of the pace of work, cardiovascular and cerebrovascular diseases have become the number one killer threatening the health and longevity of middle-aged and elderly people. According to statistics from the Ministry of Health, one-third of the first onset age of cardiovascular and cerebrovascular disease patients in my country is below 60 years old. Their morbidity, mortality, disability and recurrence rates are all very high and there are many complications. Their morbidity is as high as 13.6%, and it increases at a rate of 20,000 people per day. The mortality rate is as high as 45%, accounting for 50% of the total number of deaths. The disability rate is high, with the disability rate of stroke patients reaching 75%, and coronary heart disease patients becoming semi-laborers. The recurrence rate is high, with the recurrence rate of cardiovascular and cerebrovascular diseases (myocardial infarction, cerebral infarction) within five years reaching 42%. There are many respiratory, digestive and urinary system diseases caused by cardiovascular and cerebrovascular accidents. Among them, hypertension, stroke and coronary heart disease are representative diseases of cardiovascular and cerebrovascular diseases.

[0003] At present, cardiovascular and cerebrovascular diseases are mainly treated with Western medicine, and the range of drugs for symptoms is narrow. Sometimes, multiple Western medicines need to be taken, and comprehensive treatment is not possible. Moreover, the side effects of Western medicines are still very large, and there are problems such as blood pressure-lowering drugs do not have the effect of lowering blood lipids (such as nifedipine, benazepril, telmisartan, etc.), and blood lipid-lowering drugs do not have the effect of lowering blood pressure (such as lovastatin, fenofibrate, etc.).

[0004] Therefore, how to develop a Chinese medicine composition with the functions of lowering blood pressure, lowering blood lipids and preventing and treating cardiovascular and cerebrovascular diseases according to the symptoms and constitution of people with hyperlipidemia and hypertension is an urgent problem to be solved by those skilled in the art. Summary of the invention

[0005] In view of this, the present invention provides a Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] A traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases comprises the following raw materials: ginkgo leaf, sophora japonica flower, kudzu root, ginkgo, codonopsis pilosula, chrysanthemum, nelumbosine, jujube, angelica, gastrodia elata, purslane, wolfberry, selfheal, cornus officinalis, sappan wood, eucommia leaf, lithospermum officinale and liquorice.

[0008] Preferably, the composition is used to treat cardiovascular and cerebrovascular diseases.

[0009] Furthermore, the invention comprises, by weight: 60-80 parts of ginkgo leaves, 58-70 parts of Sophora japonica flowers, 47-65 parts of Pueraria root, 40-60 parts of ginkgo, 35-55 parts of Codonopsis pilosula, 32-50 parts of chrysanthemum, 28-46 parts of lotus seed core, 25-40 parts of Ziziphus jujuba, 25-40 parts of Angelica sinensis, 23-35 parts of Gastrodia elata, 23-35 parts of Portulaca oleracea, 20-30 parts of Lycium barbarum, 20-30 parts of Prunella vulgaris, 15-25 parts of Cornus officinalis, 13-25 parts of Sappan wood, 10-20 parts of Eucommia ulmoides leaves, 5-15 parts of Lithospermum officinale and 3-11 parts of Licorice.

[0010] Preferably, the ingredient, by weight, includes: 67 parts of ginkgo leaves, 66 parts of sophora japonica flowers, 65 parts of kudzu roots, 54 parts of ginkgo nuts, 41 parts of codonopsis pilosula, 32 parts of chrysanthemums, 34 parts of lianaine, 35 parts of jujubes, 40 parts of angelica sinensis, 31 parts of gastrodia elata, 29 parts of purslane, 20 parts of wolfberries, 24 parts of selfheal, 21 parts of cornus officinalis, 25 parts of sappan wood, 17 parts of eucommia leaves, 8 parts of lithospermum officinale and 3 parts of liquorice.

[0011] Furthermore, the preparation method of nelumboline is as follows: the lotus seed core is dried and then crushed, passed through a 60-80 mesh sieve, and the lotus seed core powder is added to the alkylphenol polyoxyethylene ether aqueous solution in a ratio of lotus seed core: alkylphenol polyoxyethylene ether aqueous solution m:v=1:18-20, and ultrahigh pressure assisted extraction is performed, and nelumboline is obtained after filtering, centrifugation, and reduced pressure drying.

[0012] Preferably, the mass fraction of the alkylphenol polyoxyethylene ether aqueous solution is 1-5%; the extraction pressure is 80-120 MPa, and the extraction time is 1-5 min.

[0013] As the same inventive concept as the above technical solution, the present invention also claims protection for a method for preparing the above Chinese medicine composition, comprising the following steps:

[0014] (1) Weigh the raw materials according to the above weight parts and set aside;

[0015] (2) Sophora japonica, chrysanthemum, Sappan wood and Lithospermum officinale are dried and crushed, and passed through a 60-80 mesh sieve to obtain a mixed powder A, and the mixed powder A is added to an ethanol solution at a ratio of mixed powder A: ethanol m:v = 1:24-30, stirred evenly, subjected to microwave-assisted extraction, filtered, centrifuged, and dried under reduced pressure to obtain an extract I;

[0016] (3) Ginkgo biloba leaves, kudzu root, codonopsis pilosula, angelica, pegasus and purslane are dried and crushed, and passed through an 80-100 mesh sieve to obtain a mixed powder B, and the mixed powder B is added to distilled water at a ratio of mixed powder B: distilled water m:v=1:7-9, and after preheating, cellulase and pectinase are added to stir and enzymolyze, and the pH is adjusted. After the end, the mixture is placed in boiling water to inactivate the enzyme, filtered, centrifuged, and dried under reduced pressure to obtain extract II;

[0017] (4) Ginkgo, jujube, wolfberry, cornus officinalis, eucommia leaf and liquorice are dried and crushed, and passed through a 60-80 mesh sieve to obtain a mixed powder C, and the mixed powder C is added to distilled water at a ratio of mixed powder C: distilled water m:v = 1:15-20, stirred evenly, extracted with water bath ultrasound, filtered, centrifuged, and dried under reduced pressure to obtain extract III;

[0018] (5) The extracts I-III and nelumboine are mixed evenly, and dried under reduced pressure to obtain the traditional Chinese medicine composition.

[0019] Furthermore, in step (2), the volume concentration of the ethanol solution is 60%-70%; the microwave power is 400-600W, and the microwave time is 3-9min; and the centrifugation is 300-500rpm for 5-10min.

[0020] Furthermore, in step (3), the preheating temperature is 45-55°C; the added amounts of the cellulase and pectinase are 1-2% of the mass of the mixed powder B respectively; the enzymatic hydrolysis time is 3-5h; the pH value is 4.8-5.2; the enzyme inactivation time is 10-15min; and the centrifugation is 500-800rpm for 5-10min.

[0021] Furthermore, in step (4), the water bath temperature is 50-55° C., the ultrasonic power is 130-220 W, and the extraction time is 20-30 min; and the centrifugation is performed at 600-800 rpm for 10-16 min.

[0022] Furthermore, in steps (2)-(4), the drying is performed at 50-60° C. for 12-24 hours.

[0023] As an inventive concept identical to the above technical solution, the present invention also requests protection for the use of the above-mentioned Chinese medicine composition or the Chinese medicine composition prepared by the above-mentioned method, wherein the use is for preparing medicines, health products or foods for preventing cardiovascular and cerebrovascular diseases.

[0024] As an inventive concept identical to the above technical solution, the present invention also seeks to protect a pharmaceutical preparation for treating cardiovascular and cerebrovascular diseases, the preparation comprising the above composition and a pharmaceutically acceptable carrier.

[0025] It can be seen from the above technical solution that, compared with the prior art, the present invention discloses a Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof, with the following beneficial effects:

[0026] The present invention combines the above-mentioned raw materials and extracts the effective ingredients of traditional Chinese medicine. Each extracted active ingredient exerts different effects and produces a synergistic effect among the multiple effects. Comprehensive conditioning is performed from multiple aspects such as the lung, liver, heart, kidney, spleen, etc., effectively improving the patient's immune repair ability, having the effects of lowering blood lipids and blood sugar, lowering blood pressure, and protecting the heart and brain, having a significant therapeutic effect on cardiovascular and cerebrovascular diseases, and can provide a theoretical basis for the research of new drugs for cardiovascular and cerebrovascular diseases.

[0027] The traditional Chinese medicine composition prepared by the present invention can improve the cardiac T wave of patients with myocardial ischemia, and also has strong antioxidant capacity, can improve the activity of GSH-Px and SOD in myocardial tissue, and can inhibit the lipid peroxidation process, reduce the activity of lipid peroxide MDA, reduce the damage of oxygen free radicals to the myocardium, and protect the ischemic myocardium.

[0028] Compared with commercially available drugs, the pharmaceutical composition of the present invention has the advantages of mildness, fewer side effects and less irritation of traditional Chinese medicine, and the preparation method of the drug is simple, the material source is wide, and it is suitable for promotion and application. DETAILED DESCRIPTION

[0029] The following will be described clearly and completely in conjunction with the technical solution of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0030] Ginkgo leaves: It is mild in nature, sweet, bitter and astringent in taste, and enters the heart meridian and lung meridian. It contains effective ingredients such as ginkgolide, isorhamnetin, kaempferol, quercetin, etc., which can improve cerebral circulation and protect brain cells and blood-brain barrier; it can reduce myocardial oxygen consumption, protect ischemic myocardium, reduce the occurrence of arrhythmias, and dilate blood vessels.

[0031] Sophora flower: It is mild in nature and bitter in taste. It has the effects of clearing heat, cooling blood, stopping bleeding and lowering blood pressure. The quercetin it contains can enhance the resistance of capillaries, reduce vascular permeability, and restore the elasticity of fragile blood vessels, thereby lowering blood lipids and preventing vascular sclerosis.

[0032] Pueraria root: It is cool in nature, sweet and spicy in taste. The total flavonoids and puerarin it contains can regulate heart function and metabolism, dilate coronary blood vessels and cerebral blood vessels, regulate blood lipids and blood sugar, and promote hematopoietic function.

[0033] Ginkgo: It is mild in nature, sweet and bitter in taste, and enters the lung and kidney meridians. It can lower serum cholesterol, reduce aortic output, and increase coronary artery flow.

[0034] Codonopsis pilosula: It is mild in nature and sweet in taste. It has the effects of tonifying the middle and replenishing Qi, harmonizing the stomach and promoting body fluid, removing phlegm and relieving cough. It also has the effect of resisting myocardial ischemia and hypoxia.

[0035] Chrysanthemum: It is slightly cold in nature, sweet and bitter in taste, and belongs to the lung and liver meridians. It has the effects of antibacterial, dilating coronary arteries, increasing coronary flow, and improving myocardial oxygen consumption.

[0036] Nelumboine: Nelumboine is extracted from lotus seed core. It has a strong and lasting antihypertensive effect. It can also reduce the area of ​​myocardial infarction, alleviate the damage to myocardial cells, and protect the myocardium from ischemia-reperfusion injury.

[0037] Jujube: sweet in taste, neutral in nature, enters the liver meridian, gallbladder meridian, and heart meridian. It has the effects of nourishing the liver, calming the mind, astringing sweat, and promoting body fluid. The triterpenoid saponins, flavonoids, triterpenes, alkaloids and other ingredients it contains can lower blood pressure, lower blood lipids, and increase coronary artery flow in the cardiovascular and cerebrovascular system.

[0038] Angelica: sweet in taste, warm in nature, enters the liver, heart, and spleen meridians, has the effect and function of reducing platelet aggregation and anti-thrombosis; and has the function of promoting the hematopoietic system; it can also play a role in lowering blood lipids, blood sugar and anti-atherosclerosis.

[0039] Gastrodia elata: It is mild in nature, sweet in taste, and enters the liver meridian. It has sedative, analgesic, and anticonvulsant effects. Gastrodia elata polysaccharides can enhance the body's nonspecific immunity, cellular immunity, and anti-inflammatory effects, as well as inhibit platelet aggregation and protect myocardial cells.

[0040] Purslane: It is cold in nature and sour in taste. It has the effects of clearing away heat and detoxifying, cooling blood and stopping bleeding. Its active ingredients can affect the respiratory system and cardiovascular and cerebrovascular systems.

[0041] Lycium barbarum: It is mild in nature, sweet in taste, and enters the liver and kidney meridians. It has the effects of nourishing the liver and kidneys, improving intelligence and improving eyesight. It can also lower blood sugar, promote hematopoietic function, and inhibit the heart's cholinergic effect.

[0042] Prunella Vulgaris: It is cold in nature, pungent and bitter in taste, and enters the liver meridian and gallbladder meridian. It has antihypertensive, antiarrhythmic, anti-inflammatory, immunosuppressive, hypoglycemic, antibacterial, antiviral, and anti-cytotoxic effects.

[0043] Cornus officinalis: It is mild in nature, sour and astringent in taste, and enters the liver and kidney meridians. It has the effects of nourishing the liver and kidneys, astringing and strengthening the lungs, and can be used to improve cardiac function and hemodynamics.

[0044] Su Mu: It is mild in nature, sweet and salty in taste, and enters the heart, liver, and spleen meridians. It has the effects of promoting blood circulation, removing blood stasis, reducing swelling and relieving pain. Its active ingredients can reduce the expression of inflammatory factors and improve the level of atherosclerosis.

[0045] Eucommia leaves: warm in nature, slightly spicy in taste, enter the liver meridian and kidney meridian, have the effect of nourishing the liver and kidney, strengthening the muscles and bones, but also have the effect of increasing coronary blood flow, lowering blood pressure, lowering blood lipids, and improving sugar metabolism.

[0046] Lithospermum: It is cold in nature, sweet and salty in taste, and enters the heart and liver meridians. It has anti-inflammatory, antipyretic, sedative, analgesic, anti-pathogenic and anti-tumor effects. The shikonin it contains can reduce oxidative stress response, thereby improving cardiac function and reducing the expression of proteins in rats with myocardial infarction.

[0047] Licorice: It is mild in nature, sweet in taste, and enters the heart meridian, stomach meridian, spleen meridian, and lung meridian. It has the effects of tonifying the spleen and stomach, replenishing qi and restoring the pulse.

[0048] Example 1

[0049] A Chinese medicine composition for treating cardiovascular and cerebrovascular diseases, comprising the following raw materials in parts by weight: 60 parts of ginkgo leaves, 62 parts of sophora japonica flowers, 59 parts of kudzu roots, 60 parts of ginkgo nuts, 48 ​​parts of codonopsis pilosula, 38 parts of chrysanthemums, 28 parts of nelumbosine, 30 parts of jujube, 35 parts of angelica, 35 parts of gastrodia, 32 parts of purslane, 23 parts of wolfberries, 20 parts of selfheal, 18 parts of cornus officinalis, 21 parts of sappan wood, 20 parts of eucommia leaves, 12 parts of lithospermum officinale and 6 parts of liquorice;

[0050] The preparation method is as follows:

[0051] (1) Weigh the raw materials according to the above weight parts and set aside;

[0052] (2) Preparation of nelumboline: Dry the lotus seed core and then grind it, pass it through a 60-mesh sieve, add the lotus seed core powder to a 1% alkylphenol polyoxyethylene ether aqueous solution in a ratio of lotus seed core: alkylphenol polyoxyethylene ether aqueous solution m:v=1:18, perform ultrahigh pressure assisted extraction at an extraction pressure of 80 MPa for 5 minutes, filter, centrifuge at 300 rpm for 10 minutes, and dry under reduced pressure at 45°C for 18 hours to obtain nelumboline;

[0053] (3) Sophora japonica, chrysanthemum, Sappan wood and Lithospermum officinale were dried at 50°C for 24 hours, then crushed and passed through a 60-mesh sieve to obtain a mixed powder A. The mixed powder A was added to an ethanol solution with a volume concentration of 60% according to a ratio of mixed powder A: ethanol (m:v) = 1:24, and the mixture was stirred evenly. The mixture was extracted for 6 minutes under a microwave power of 450 W, filtered, centrifuged at 350 rpm for 3 minutes, and dried under reduced pressure at 50°C for 24 hours to obtain extract I.

[0054] (4) Ginkgo biloba leaves, Pueraria root, Codonopsis pilosula, Angelica sinensis, Pegasus and Portulaca oleracea were dried at 55°C for 18 hours and then crushed and passed through a 90-mesh sieve to obtain a mixed powder B. The mixed powder B was added to distilled water at a ratio of mixed powder B: distilled water (m:v=1:7), and after preheating to 50°C, 1% cellulase (10000 U / g) and 1.5% pectinase (1500 U / g) were added respectively and stirred for enzymolysis for 3 hours, and the pH was adjusted to 4.8. After the end, the mixture was placed in boiling water for 12 minutes to inactivate the enzyme, filtered, centrifuged at 500 rpm for 10 minutes, and dried under reduced pressure at 55°C for 18 hours to obtain extract II;

[0055] (5) Ginkgo, jujube, wolfberry, cornus officinalis, eucommia leaf and liquorice were dried at 60°C for 12 hours, crushed and passed through an 80-mesh sieve to obtain a mixed powder C, and the mixed powder C was added to distilled water at a ratio of mixed powder C: distilled water m:v = 1:18, stirred evenly, and extracted in a water bath with ultrasonic waves at 55°C and 220W for 20 minutes, filtered, centrifuged at 600 rpm for 16 minutes, and dried under reduced pressure at 60°C for 12 hours to obtain extract III;

[0056] (6) The extracts I-III and nelumboline were mixed evenly, and dried under reduced pressure at 60° C. for 12 h to obtain a composition.

[0057] Example 2

[0058] A Chinese medicine composition for treating cardiovascular and cerebrovascular diseases, comprising the following raw materials in parts by weight: 67 parts of ginkgo leaves, 66 parts of Sophora japonica flowers, 65 parts of Pueraria root, 54 parts of ginkgo, 41 parts of Codonopsis pilosula, 32 parts of Chrysanthemum, 34 parts of nelumbosine, 35 parts of Ziziphus jujuba, 40 parts of Angelica sinensis, 31 parts of Gastrodia elata, 29 parts of Portulaca oleracea, 20 parts of Lycium barbarum, 24 parts of Prunella vulgaris, 21 parts of Cornus officinalis, 25 parts of Sappan wood, 17 parts of Eucommia ulmoides leaves, 8 parts of Lithospermum officinale and 3 parts of Licorice;

[0059] The preparation method is as follows:

[0060] (1) Weigh the raw materials according to the above weight parts and set aside;

[0061] (2) Preparation of nelumboline: Dry the lotus seed core and then grind it, pass it through an 80-mesh sieve, add the lotus seed core powder to a 5% alkylphenol polyoxyethylene ether aqueous solution in a ratio of lotus seed core: alkylphenol polyoxyethylene ether aqueous solution m:v=1:20, perform ultrahigh pressure assisted extraction at an extraction pressure of 120 MPa for 1 min, filter, centrifuge at 500 rpm for 5 min, and dry under reduced pressure at 48°C for 12 h to obtain nelumboline;

[0062] (3) Sophora japonica, chrysanthemum, Sappan wood and Lithospermum officinale were dried at 55° C. for 18 h, then crushed and passed through an 80-mesh sieve to obtain a mixed powder A. The mixed powder A was added to an ethanol solution with a volume concentration of 65% according to a ratio of mixed powder A: ethanol (m:v) = 1:27, stirred evenly, and assisted with extraction at a microwave power of 400 W for 9 min. After filtering, centrifuging at 250 rpm for 6 min, and drying under reduced pressure at 55° C. for 18 h, extract I was obtained.

[0063] (4) Ginkgo biloba leaves, Pueraria root, Codonopsis pilosula, Angelica sinensis, Pegasus and Portulaca oleracea were dried at 60°C for 12 hours and then crushed and passed through a 100-mesh sieve to obtain a mixed powder B. The mixed powder B was added to distilled water at a ratio of mixed powder B: distilled water (m:v=1:9), and after preheating to 50°C, 1.5% cellulase (10,000 U / g) and 2% pectinase (1500 U / g) were added respectively and stirred for enzymolysis for 4 hours, and the pH was adjusted to 5.0. After the end, the mixture was placed in boiling water for 10 minutes to inactivate the enzyme, filtered, centrifuged at 800 rpm for 5 minutes, and dried under reduced pressure at 60°C for 12 hours to obtain extract II;

[0064] (5) Ginkgo, jujube, wolfberry, cornus officinalis, eucommia leaf and liquorice were dried at 50°C for 24 hours, crushed and passed through a 60-mesh sieve to obtain a mixed powder C, and the mixed powder C was added to distilled water at a ratio of mixed powder C: distilled water m:v = 1:20, stirred evenly, and extracted in a water bath ultrasonically at 50°C and 130W for 30 minutes, filtered, centrifuged at 800 rpm for 10 minutes, and dried under reduced pressure at 50°C for 24 hours to obtain extract III;

[0065] (6) The extracts I-III and nelumboine were mixed evenly, and dried under reduced pressure at 55° C. for 18 h to obtain a composition.

[0066] Example 3

[0067] A Chinese medicine composition for treating cardiovascular and cerebrovascular diseases, comprising the following raw materials in parts by weight: 74 parts of ginkgo leaves, 70 parts of Sophora japonica flowers, 53 parts of Pueraria root, 40 parts of ginkgo, 55 parts of Codonopsis pilosula, 44 parts of chrysanthemum, 46 parts of nelumbosine, 25 parts of Ziziphus jujuba, 30 parts of Angelica sinensis, 25 parts of Gastrodia elata, 35 parts of Portulaca oleracea, 26 parts of Lycium barbarum, 30 parts of Prunella vulgaris, 15 parts of Cornus officinalis, 17 parts of Sappan wood, 10 parts of Eucommia ulmoides leaves, 15 parts of Lithospermum officinale and 9 parts of Licorice;

[0068] The preparation method is as follows:

[0069] (1) Weigh the raw materials according to the above weight parts and set aside;

[0070] (2) Preparation of nelumboline: Dry the lotus seed core and then grind it, pass it through a 70-mesh sieve, add the lotus seed core powder to a 2.5% alkylphenol polyoxyethylene ether aqueous solution in a ratio of lotus seed core: alkylphenol polyoxyethylene ether aqueous solution m:v=1:19, perform ultrahigh pressure assisted extraction at an extraction pressure of 100 MPa for 3 minutes, filter, centrifuge at 400 rpm for 8 minutes, and dry under reduced pressure at 43°C for 20 hours to obtain nelumboline;

[0071] (3) Sophora japonica, chrysanthemum, Sappan wood and Lithospermum officinale were dried at 60°C for 12 h, then crushed and passed through a 60-mesh sieve to obtain a mixed powder A. The mixed powder A was added to an ethanol solution with a volume concentration of 70% according to a ratio of mixed powder A: ethanol (m:v) = 1:30, stirred evenly, and assisted with extraction for 3 min under a microwave power of 500 W. After filtering, centrifuging at 300 rpm for 5 min, and drying under reduced pressure at 60°C for 12 h, extract I was obtained.

[0072] (4) Ginkgo biloba leaves, kudzu root, codonopsis, angelica, gypsophila and purslane were dried at 50°C for 24 hours and then crushed and passed through an 80-mesh sieve to obtain a mixed powder B. The mixed powder B was added to distilled water at a ratio of mixed powder B: distilled water (m:v=1:8), and after preheating to 50°C, 2% cellulase (10000 U / g) and 1% pectinase (1500 U / g) were added respectively and stirred for enzymolysis for 5 hours, and the pH was adjusted to 5.2. After the end, the mixture was placed in boiling water for 15 minutes to inactivate the enzyme, filtered, centrifuged at 650 rpm for 7 minutes, and dried under reduced pressure at 50°C for 24 hours to obtain extract II;

[0073] (5) Ginkgo, jujube, wolfberry, cornus officinalis, eucommia leaf and liquorice were dried at 55°C for 18 hours, crushed and passed through a 70-mesh sieve to obtain a mixed powder C, and the mixed powder C was added to distilled water at a ratio of mixed powder C: distilled water m:v = 1:15, stirred evenly, and extracted in a water bath with ultrasonic waves at 53°C and 175W for 25 minutes, filtered, centrifuged at 700 rpm for 13 minutes, and dried under reduced pressure at 55°C for 18 hours to obtain extract III;

[0074] (6) The extracts I-III and nelumboline were mixed evenly, and dried under reduced pressure at 50° C. for 24 h to obtain a composition.

[0075] Example 4

[0076] A Chinese medicine composition for treating cardiovascular and cerebrovascular diseases, comprising the following raw materials in parts by weight: 80 parts of ginkgo leaves, 58 parts of sophora japonica flowers, 47 parts of kudzu roots, 47 parts of ginkgo nuts, 55 parts of codonopsis pilosula, 50 parts of chrysanthemums, 40 parts of nelumbosine, 40 parts of jujube, 25 parts of angelica sinensis, 28 parts of gastrodia elata, 25 parts of purslane, 30 parts of wolfberries, 27 parts of selfheal, 25 parts of cornus officinalis, 13 parts of sappan wood, 13 parts of eucommia leaves, 5 parts of lithospermum officinale and 11 parts of liquorice;

[0077] The preparation method is the same as that in Example 2.

[0078] Experimental Example 1 Evaluation of the lipid-lowering effects of different Chinese medicine compositions

[0079] (1) Experimental animal grouping and drug administration

[0080] 200 Kunming mice (weight 18-22g) were selected and raised in a mouse box in a 22-25°C environment, with 20 mice per group, fed with ordinary feed, purified water, and adaptive free diet for one week. During the experiment, they were randomly divided into a blank group, a model group, a simvastatin group, an embodiment 1-4 group, and an experiment AC group according to body weight, with 20 mice in each group. The blank group was fed with a basic feed, and the remaining groups were all given a high-fat feed formula of (77.5% basic feed, 2% cholesterol, 10% lard, 10% egg yolk powder, 0.5% sodium deoxycholate). After a week of high-fat diet, the mice were gavaged once at the same time every day at a volume of 10m L / kg, and the blank and model groups were gavaged with an equal volume of normal saline, and fed for 5 consecutive weeks, and the weight of the mice was detected every week.

[0081] The simvastatin group was given a dose of 10 mg / kg, and the Example 1-4 and Experiment A and B groups were given a dose of 20 mg / kg, and the solvent was normal saline;

[0082] Among them, the test group A is the composition in patent number CN114306519A, and the composition comprises the following components in parts by weight: 30 parts of salvia miltiorrhiza, 17-18 parts of kudzu root, 14 parts of safflower, 4 parts of leech, 10 parts of epimedium, 15 parts of gastrodia elata, and 12-13 parts of hawthorn;

[0083] Test group B is based on the composition of Example 2, except that nelumboine, flos sophorae, jujube, sappan wood, and lithospermum officinale are removed, and the rest is the same;

[0084] Experiment C group is based on the composition of Example 2, but changes the preparation method of nelumboline, specifically: the lotus seed core is dried and crushed, passed through an 80-mesh sieve, the lotus seed core powder is added to distilled water in a ratio of lotus seed core: distilled water m:v=1:10, reflux extraction is performed at 80°C for 3 times, each time for 2 hours, the extracts are combined and centrifuged, and after reduced pressure drying, nelumboline can be obtained, and the rest is the same.

[0085] (2) Effects of different compositions on body weight of high-fat mice

[0086] During the experiment, the mice's diet, drinking water, activities, and coat color were observed and recorded daily. The mice were weighed once a week, recorded, and observed. The results are shown in Tables 1 and 2.

[0087] Table 1 Effects of different compositions on body weight of high-fat mice

[0088]

[0089] Table 2 Effects of different compositions on body weight of high-fat mice

[0090]

[0091]

[0092] As can be seen from Tables 1 and 2, after 8 weeks of administration, the weight of mice in the high-fat model group increased significantly and was significantly higher than that in the blank group. After treatment with the compositions of Examples 1-4 of the present invention, the weight of mice in each group decreased significantly, among which the composition of Example 2 had the best effect in reducing weight. After removing some raw materials and changing the preparation method, in Test Groups A and C, although the degree of weight reduction of mice after administration was lower than that of the composition group, it was significantly lower than that of the model group, indicating that there was a synergistic effect between the compositions of the present invention, and the synergistic effect could significantly reduce the weight of high-fat model mice. Test Group B was a composition in the prior art, which could also reduce the weight of high-fat model mice, but the degree of reduction was significantly lower than that of the composition of the present invention.

[0093] (3) Effects of different compositions on the levels of TC and TG in the serum of hyperlipidemia mice

[0094] After the 8th week, all mice were fasted but not watered for 12 h, their eyeballs were removed and blood was collected into centrifuge tubes, which were centrifuged (3000 r / min, 4°C) to separate serum. The levels of total cholesterol (TC) and triglyceride (TG) in serum were determined according to the test requirements of the kit. The results are shown in Table 3.

[0095] Table 3 Effects of different compositions on the levels of TC and TG in the serum of hyperlipidemia mice

[0096] Group TC(mmol / L) TG (mmol / L) Blank group 2.54±0.36 1.71±0.23 Model Group 4.82±0.61 3.56±1.03 Simvastatin group 3.04±0.38 2.25±0.72 Example 1 3.43±0.52 2.47±0.61 Example 2 3.09±0.24 2.17±0.53 Example 3 3.13±0.36 2.21±0.42 Example 4 3.37±0.63 2.33±0.35 Test Example A 3.76±0.63 2.68±0.43 Test Example B 3.62±0.54 2.59±0.52 Test Example C 3.67±0.68 2.63±0.37

[0097] As shown in Table 3, the TC and TG levels of the high-fat model group were significantly higher than those of the blank group, indicating that the mouse hyperlipidemia model was successfully established; compared with the model group, the compositions of Examples 1-4 of the present invention can significantly reduce the levels of TC and TG in serum, and the effect of the Chinese medicine composition group of the present invention is worse than that of the test groups A and B, indicating that the composition group of the present invention has a good lipid-lowering effect; the test example group C changed the preparation method of nelumboline, and although it can also lower blood lipids, the effect produced is not as good as the present invention.

[0098] Since hyperlipidemia refers to elevated levels of cholesterol or triglycerides in plasma, hyperlipidemia is mainly related to cholesterol, and elevated cholesterol is one of the most important risk factors for increased mortality from cardiovascular and cerebrovascular diseases such as coronary heart disease; the Chinese medicine composition of the present invention can effectively reduce the serum TC and TG levels of hyperlipidemia mice, and the reduction level is significantly higher than that of the model group and the experimental AC group, which indicates that the Chinese medicine composition of the present invention is more effective in treating and preventing cardiovascular and cerebrovascular diseases.

[0099] Experimental Example 2 Evaluation of the hypoglycemic effect of different Chinese medicine compositions

[0100] (1) Preparation of diabetic model mice

[0101] A total of 200 Kunming mice (weighing 18-22 g) were selected. After one week of adaptive feeding, 20 mice were randomly selected as normal controls. The remaining 180 mice were intraperitoneally injected with STZ (streptozotocin, 55 mg / kg), dissolved in 0.1 mol / L citric acid buffer (pH 4.2), once a day for 5 consecutive days to establish the model. The blank control group was injected with an equal amount of citrate buffer. After 5 days, blood was collected from the tail vein to test their fasting blood glucose. Mice with blood glucose above 11.1 mmol / L were considered diabetic model mice and included in the experiment.

[0102] (2) Grouping and drug administration

[0103] The diabetic model mice were randomly divided into groups, with 20 mice in each group, and the blood glucose values ​​of each group were similar, of which 1 group was a model control group, 1 group was a positive drug group (metformin hydrochloride was administered at a dose of 20 mg / kg), and the remaining 7 groups were Examples 1-4 of the present invention and Test AC groups (the dose was the same as that in Test Example 1); each group of mice was gavaged with the corresponding drug at a dose of 0.20 mL / 10 g body weight, and the normal control group and the model control group were gavaged with the corresponding amount of normal saline, once a day, for 28 consecutive days.

[0104] (3) Effects of different compositions on blood glucose in STZ-induced hyperglycemia model mice

[0105] After 28 days of intervention, the rats in the 9 groups were fasted for 12 hours (but not water), and then the oral glucose resistance test was performed. The blood glucose level was measured first, and then 2 g / kg glucose solution was given by gavage, and then the blood glucose level was measured at 30, 60, and 120 minutes. The test results are shown in Table 4.

[0106] Table 4 Effects of different compositions on blood glucose in STZ-induced hyperglycemia model mice

[0107]

[0108]

[0109] As shown in Table 4, at the beginning of the intervention (0min), the blood glucose of the diabetic rats increased and the glucose tolerance was impaired. The blood glucose of the rats in the model group was 22.49mmol / L, which was 3.37 times higher than that in the blank group, and the blood glucose of the rats in the positive drug group, the Example 1-4 group and the Test Example AC group was lower than that in the model group; in the first 30min, the blood glucose levels of all rats increased rapidly, and after 30min, the blood glucose concentrations of each group reached a peak, and then gradually decreased, and returned to the vicinity of the initial value at 120min; compared with the model group, the blood glucose levels of the positive drug group, the Example 1-4 group and the Test Example A and B groups all decreased, but the decrease level of the composition of Example 2 was the highest, which decreased by 34.80%; and although the test AC group could significantly improve the glucose tolerance of the experimental mice, the improvement effect was weaker than the hypoglycemic effect of the Chinese medicine composition of the present invention; it can be seen that the Chinese medicine composition of the present invention has a good therapeutic effect in reducing the blood glucose value of STZ rats and improving impaired glucose tolerance.

[0110] (4) Effects of different compositions on serum insulin in STZ-induced diabetic mice

[0111] After the intragastric administration of the experiment, blood was collected from the mice’s orbits on the 22nd day, and the serum was separated by centrifugation at 3000 rpm for 10 min at 4°C. The serum insulin level was detected according to the kit instructions. The results are shown in Table 5.

[0112] Table 5 Effects of different compositions on serum insulin in STZ-induced diabetic mice

[0113]

[0114]

[0115] Insulin is a protein hormone secreted by pancreatic β cells, which participates in regulating sugar metabolism and controlling blood sugar balance, and is mainly used to treat STZ-induced diabetes. As shown in Table 5, compared with the normal control group, the serum insulin level of the model group mice was significantly reduced, indicating that after intraperitoneal injection of STZ, the insulin secretion in the mice was inhibited, the sugar metabolism was disordered, and the blood sugar in the body could not be regulated, and the model was successfully established; compared with the model group, the serum insulin levels of the positive drug group, the embodiment 1-4 group, and the test example A and B groups were all increased, but the effect of the composition of embodiment 2 was the best, which increased by 40.64%; and, although the test A, B and C groups can increase the serum insulin level of the experimental mice, the improvement effect is weaker than that of the Chinese medicine composition of the present invention; it can be seen that the Chinese medicine composition of the present invention has a good therapeutic effect on increasing the serum insulin level of STZ rats.

[0116] Experimental Example 3 Evaluation of the blood pressure lowering effect of different compositions

[0117] 180 SPF male spontaneously hypertensive rats (SHR) weighing 220-240g and 20 male Wistar-Kyoto rats (blank group) were selected and raised at a temperature of 25±1°C, a relative humidity of 55% to 65%, and alternating light and dark during the day and night. The rats were fed and drank water autonomously. After 1 week of adaptive feeding, a gavage test was performed. SHR rats were randomly divided into 9 groups, each with 20 rats, of which 1 group was a model control group, 1 group was a positive drug group (captopril was given a dose of 3 mg / kg), and the remaining 7 groups were Examples 1-4 of the present invention and Test A, B and C groups (the dose was the same as Test Example 1); mice in each group were gavaged with the corresponding drugs, and the normal control group and the model control group were gavaged with the corresponding amount of physiological saline. After 2 consecutive weeks, gavage was stopped and observed for 1 week. Blood pressure, heart rate and body weight were measured by non-invasive tail artery blood pressure determination. The results are shown in Table 6.

[0118] Table 6 Effects of different compositions on body weight, blood pressure and heart rate of SHR rats

[0119]

[0120]

[0121] As shown in Table 6, during the test, the animals in each group grew well and moved normally, and there was no significant difference in the weight of the rats among the groups; compared with the blank group, the blood pressure of the rats in the model group was significantly increased; compared with the model group, the blood pressure levels of the rats in the positive drug group, the Example 1-4 groups, and the Test Example A, B and C groups were all reduced, but the blood pressure lowering effect of the composition of Example 2 was the best, which was reduced by 32.96%; compared with the model group, the heart rate of the rats in the Example 1-4 groups and the blank group had no significant difference, which showed that the composition of the present invention did not affect the normal heart rate of the experimental rats.

[0122] Experimental Example 4 Effects of different compositions on experimental myocardial ischemia induced by pituitrin in rats

[0123] (1) Preparation of diabetic model mice

[0124] 200 Wistar rats (weight 256.2±10.6g) were selected. After one week of adaptive feeding, 20 rats were randomly selected as normal controls. The remaining 180 mice were injected with posterior pituitary hormone at a dose of 1.5IU / kg through the sublingual vein, which caused coronary artery contraction and myocardial ischemia and hypoxia, and also caused systemic small blood vessels to contract, increasing the afterload of the heart, further aggravating myocardial ischemia and hypoxia, indicating that the rat myocardial ischemia model was successfully established.

[0125] (2) Grouping and drug administration

[0126] Myocardial ischemia model rats were randomly divided into groups, with 20 rats in each group, of which 1 group was a model control group, 1 group was a positive drug group (diltiazem was administered at a dose of 5 mg / kg), and the remaining 7 groups were Examples 1-4 of the present invention and Test AC groups (the dose was the same as that of Test Example 1); the rats in each group were continuously gavaged for 7 days according to the dosage of each group, and the normal control group and the posterior pituitary ischemia group were given the same volume of sodium chloride injection.

[0127] (3) Effects of different compositions on the absolute value of T wave changes in the pituitrin-induced myocardial ischemia model in rats

[0128] On the 7th day, after intraperitoneal administration, urethane was injected for anesthesia. After intraperitoneal administration for 40 minutes, ECG of lead II was recorded for 1 minute as the pre-ischemic value. The posterior pituitary ischemic group, the positive control group and the Example 1-8 groups were injected with posterior pituitary by sublingual vein to cause myocardial ischemia. ECG at 30 seconds, 1 minute, 5 minutes, 10 minutes and 15 minutes after the administration of posterior pituitary was recorded as the post-ischemic value. The absolute value of T wave change in each group was calculated. The measurement results are shown in Table 7.

[0129] Table 7 Effects of different compositions on the absolute value of T wave changes in the rat myocardial ischemia model induced by pituitary hormone

[0130] Group 30s 1min 5min 10min 15min Blank group 0.013±0.002 0.014±0.003 0.011±0.001 0.010±0.002 0.011±0..003 Model Group 0.104±0.013 0.098±0.014 0.107±0.037 0.102±0.035 0.098±0.021 Positive control group 0.045±0.006 0.037±0.002 0.034±0.001 0.031±0.006 0.028±0.003 Example 1 0.052±0.009 0.049±0.004 0.045±0.009 0.043±0.004 0.040±0.005 Example 2 0.032±0.002 0.030±0.002 0.027±0.003 0.028±0.002 0.025±0.001 Example 3 0.043±0.003 0.040±0.003 0.035±0.002 0.036±0.005 0.034±0.003 Example 4 0.056±0.015 0.053±0.015 0.048±0.006 0.045±0.003 0.041±0.006 Test Example A 0.093±0.024 0.092±0.038 0.090±0.035 0.092±0.038 0.090±0.037 Test Example B 0.067±0.018 0.064±0.022 0.061±0.024 0.58±0.011 0.059±0.014 Test Example C 0.089±0.023 0.090±0.039 0.088±0.015 0.090±0.029 0.087±0.025

[0131] As shown in Table 7, after sublingual intravenous injection of posterior pituitary hormone, compared with the normal control group, the absolute value of T wave change in the posterior pituitary hormone ischemia group at each time point was significantly increased, indicating that the model was successfully established; compared with the model group, the absolute value of T wave change in the positive control group and Examples 1-4, and Test Example B group at each time point was significantly reduced, and there was no significant change in the T wave change value at each time point in Test Examples A and C groups, indicating that the drugs of Test Examples A and C had no effect on improving myocardial ischemia in rats. The degree of reduction in the absolute value of T wave change at each time point in Example 1 and Example 4 was weaker than that in the positive control group and Examples 2 and 3, indicating that the drugs of Example 1 and Example 4 improved myocardial ischemia in rats, but the degree of improvement was not as good as that of the positive control drug and the drugs of Examples 2 and 3. The absolute value of T wave change at each time point in Example 2 was the highest, indicating that the drug of Example 2 had a very large improvement on myocardial ischemia in rats, and the degree of improvement was higher than that of the positive control drug; thus, it can be shown that the composition of the present invention has a good improvement effect on myocardial ischemia caused by inhibiting posterior pituitary hormone.

[0132] (4) Determination of GSH-Px, SOD and MDA in serum of rat myocardial ischemia model induced by pituitary hormone by different compositions

[0133] Blood was collected from rats through abdominal aorta cannulation, and a portion of plasma was taken to separate serum. The contents of GSH-Px, SOD, and MDA in serum were determined according to the instructions of the kit. The results are shown in Table 8.

[0134] Table 8 Determination results of GSH-Px, SOD and MDA in serum of rat myocardial ischemia model

[0135] Group GSH-Px(U / L) SOD (nmol / mL) MDA (U / mL) Blank group 277.56±18.14 2.78±0.74 201.38±34.79 Model Group 98.96±8.72 7.05±1.92 160.14±26.50 Positive control group 208.90±47.72 3.94±0.78 192.32±11.49 Example 1 203.45±33.54 4.01±1.46 188.78±20.22 Example 2 213.53±45.15 3.84±0.78 196.57±21.92 Example 3 209.43±37.41 3.92±0.90 193.22±20.54 Example 4 201.90±57.73 4.05±1.04 184.20±23.67 Test Example A 197.52±31.47 4.15±1.21 175.17±19.53 Test Example B 195.58±30.86 4.10±1.08 186.08±20.14 Test Example C 185.49±28.36 4.21±1.35 173.65±22.52

[0136] Glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) are endogenous enzyme scavengers that can counteract the oxidative damage of free radicals, and malondialdehyde (MDA) is a stable aldehyde product of lipid peroxidation, which is widely used to reflect the level of oxidative stress. As shown in Table 8, compared with the model group, after treatment with the positive control group, the embodiment 1-4 group and the test example AC group, the GSH-Px and SOD activities in the rat serum were increased to a certain extent, and the MDA content was reduced. Among them, the GSH-Px and SOD activities in the rat serum can be significantly increased with the embodiment 2, and the MDA content in the rat serum can be significantly reduced; thus, it can be explained that the Chinese medicine composition prepared by the present invention has a strong antioxidant capacity, can improve the activity of GSH-Px and SOD in the myocardial tissue, and can inhibit the lipid peroxidation process, reduce the lipid peroxide MDA activity, reduce the damage of oxygen free radicals to the myocardium, protect the ischemic myocardium, and treat ischemic heart disease.

[0137] In this specification, each embodiment is described in a progressive manner, and each embodiment focuses on the differences from other embodiments, and the same and similar parts between the embodiments can be referred to each other. The above description of the disclosed embodiments enables professionals and technicians in this field to implement or use the present invention. Various modifications to these embodiments will be obvious to professionals and technicians in this field, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to these embodiments shown in this article, but will comply with the widest range consistent with the principles and novel features disclosed herein.

Claims

1. Use of a composition in the preparation of a medicament for improving myocardial ischemia caused by vasopressin, characterized in that: The composition is a traditional Chinese medicine composition, and the raw materials of the composition are, by weight: 60-80 parts of ginkgo leaves, 58-70 parts of Sophora japonica flowers, 47-65 parts of Pueraria root, 40-60 parts of ginkgo nuts, 35-55 parts of Codonopsis pilosula, 32-50 parts of chrysanthemum, 28-46 parts of lotus seed core, 25-40 parts of Ziziphus jujuba, 25-40 parts of Angelica sinensis, 23-35 parts of Gastrodia elata, 23-35 parts of Portulaca oleracea, 20-30 parts of Lycium barbarum, 20-30 parts of Prunella vulgaris, 15-25 parts of Cornus officinalis, 13-25 parts of Sappan wood, 10-20 parts of Eucommia ulmoides leaves, 5-15 parts of Lithospermum officinale and 3-11 parts of Licorice.

Images